The FDA has published its “Enhanced Approach for Sampling and Testing (EAST) program which proactively monitors the quality of medicines available to American patients and consumers”. The new program utilizes faster, modern testing techniques and traditional methods to efficiently and effectively evaluate more drug products. Under this program, FDA will purchase drug products from retain pharmacy outlets and wholesalers for testing and will publish the test results.
The goal is to provide a broader real time evaluation of the quality attribute of marketed drug products from both domestic and international manufacturers. The FDA says drug samples will be collected in a manner “to ensure broad representation across manufacturers, therapeutic classes, and geographic regions, including both domestic and internationally manufactured drugs”.
The FDA testing program has been updated to better understand the quality of marketed drug products and bolster confidence in our nation’s drug supply. Recent articles and broadcast interviews have raised significant questions about the quality of certain drug products. This coverage has negatively affected public perception of both brand-name and generic medicines and has eroded confidence in the FDA approval process.
FDA has always tested product samples under a routine surveillance program; however, this new program will employ methodology that will enable the Agency to perform significantly more sample testing. The Agency plans to publish the results of the testing under the EAST program and already does so under the previous surveillance program (see here and scroll down to the data). The FDA says, “[A]dditional drug quality surveillance is provided by FDA’s Enhanced Approach for Sampling and Testing (EAST) that proactively monitors the quality of medicines available to American patients and consumers”.

